• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Zoledronic acid may increase bone density in frail elderly women

byShayna BejaimalandJames Jiang
April 14, 2015
in Chronic Disease, Endocrinology
Reading Time: 2 mins read
Statin therapy does not prevent osteoporotic fractures [JUPITER trial]
Share on FacebookShare on TwitterShare on LinkedIn

1. A single dose of zoledronic acid improved bone mineral density over 2 years in frail elderly women.

2. Rates of fracture or mortality did not differ significantly between zoledronic acid treatment and placebo groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Although as many as 85% of frail elderly adults living in long-term homes have osteoporosis, the current use of bisphosphonate therapy is low. Previous randomized controlled trials studying osteoporosis have not examined the efficacy of bisphosphonates in this population, and given physiological differences in the elderly, the efficacy and safety of bisphosphonates may be vastly different. This study aimed to determine the efficacy and safety of zoledronic acid to treat osteoporosis in frail elderly women living in long-term care facilities.

In this randomized controlled trial, a single dose of zoledronic acid improved bone mineral density in the population over 2 years. However, there was no significant decrease in rates of fracture or mortality across groups. Strengths of this study include studying this outcome in a novel yet important patient population. Limitations include the specific patient population selected, which may limit the generalizability of the results. Moreover, this study was not sufficiently powered to determine zoledronic acid’s effect on fracture rates, so further study regarding this question is warranted.

Click to read the study in JAMA Internal Medicine

RELATED REPORTS

Bisphosphonates may reduce short-term pain in complex regional pain syndrome 

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

Relevant Reading: Once-yearly Zoledronic acid for treatment of postmenopausal osteoporosis

In-Depth [randomized controlled trial]: This double-blind, randomized controlled trial was performed in Pittsburgh, Pennsylvania from December 2007 to March 2012, and randomized a total of 181 frail elderly women to either a single dose of zoledronic acid 5 mg with vitamin D and calcium, or placebo (i.e., vitamin D and calcium alone). The primary outcome was hip and spine bone mineral density at 12 and 24 months. Secondary outcomes included rate of fracture and mortality. Data was analyzed using linear mixed model regression, χ2 and Fisher exact tests.

After randomization, the treatment group included more women with frailty, falls history, diabetes and anticonvulsant use. Women in the treatment group had a greater mean (standard error, SE) bone mineral density changes in the hip and spine at 24 months as compared to the placebo group: 2.6% (0.6%) vs. -1.5% (0.7%); p < 0.001 and 4.5% (0.8%) vs. 0.7% (0.5%); p < 0.001. Similar differences were also seen at the 12-month mark. Differences in fracture rates were not significant between groups – 20% for the treatment group and 16% for the placebo group (OR 1.30; 95%CI 0.61-2.78). Mortality rates also did not differ significantly across groups (OR 1.24; 95% CI 0.54-2.86).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bisphosphonatesosteoporosis
Previous Post

Study participants prefer less demanding consent

Next Post

Cutaneous microneedle flu vaccination reduces skin irritation and improves effectiveness [PreClinical]

RelatedReports

Pain relief collage: an engraved nerve cell with a fading teal signal, a willow sprig with catkins and over-ear headphones
Chronic Disease

Bisphosphonates may reduce short-term pain in complex regional pain syndrome 

December 15, 2025
Inflammatory bowel disease collage: a calm young woman in a sweater beside a large intestine drawing and a hot water bottle
Chronic Disease

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

April 17, 2025
#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women
StudyGraphics

#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women

January 22, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Chronic Disease

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

January 13, 2025
Next Post
Vaccines for predicted influenza strains may provide wide protection [PreClinical]

Cutaneous microneedle flu vaccination reduces skin irritation and improves effectiveness [PreClinical]

Nonleg venous thromboses associated with PE, longer ICU stay

Patient screening and monitoring improve dabigatran (Pradaxa) adherence

Gestational diabetes linked to autism spectrum disorder

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2MM: AI Roundup- PTSD Prediction, Gait as a Biomarker, Faster Cardiac MRI, and Perinatal Mental Health Chatbots [November 12th, 2026]
  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.